COMPASS Pathways plc (CMPS)

Market Cap	455.57M
Revenue (ttm)	n/a
Net Income (ttm)	-86.23M
Shares Out	42.58M
EPS (ttm)	-2.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,639
Open	10.83
Previous Close	10.72
Day's Range	10.64 - 10.92
52-Week Range	6.54 - 21.50
Beta	2.29
Analysts	Buy
Price Target	46.83 (+337.66%)
Earnings Date	Feb 23, 2023

About CMPS

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Ki...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: CMPS

Analyst Forecast

According to 18 analysts, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $46.83, which is an increase of 337.66% from the latest price.

Price Target

$46.83

(337.66% upside)

Analyst Consensus: Buy